Skip to main content
Top
Published in: BMC Infectious Diseases 1/2021

Open Access 01-12-2021 | Chloroquin | Research article

Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand’s university-based referral hospital

Authors: Rujipas Sirijatuphat, Yupin Suputtamongkol, Nasikarn Angkasekwinai, Navin Horthongkham, Methee Chayakulkeeree, Pinyo Rattanaumpawan, Pornpan Koomanachai, Susan Assanasen, Yong Rongrungruang, Nitipatana Chierakul, Ranistha Ratanarat, Anupop Jitmuang, Walaiporn Wangchinda, Wannee Kantakamalakul

Published in: BMC Infectious Diseases | Issue 1/2021

Login to get access

Abstract

Background

The epidemiology and outcomes of COVID-19 patients in Thailand are scarce.

Methods

This retrospective cohort study included adult hospitalized patients who were diagnosed with COVID-19 at Siriraj Hospital during February 2020 to April 2020.

Results

The prevalence of COVID-19 was 7.5% (107 COVID-19 patients) among 1409 patients who underwent RT-PCR for SARS-CoV-2 detection at our hospital during the outbreak period. Patients with COVID-19 presented with symptoms in 94.4%. Among the 104 patients who were treated with antiviral medications, 78 (75%) received 2-drug regimen (lopinavir/ritonavir or darunavir/ritonavir plus chloroquine or hydroxychloroquine), and 26 (25%) received a 3-drug regimen with favipiravir added to the 2-drug regimen. Disease progression was observed in 18 patients (16.8%). All patients with COVID-19 were discharged alive.

Conclusions

The prevalence of COVID-19 was 7.5% among patients who underwent RT-PCR testing, and 10% among those having risk factors for COVID-19 acquisition. Combination antiviral therapies for COVID-19 patients were well-tolerated and produced a favorable outcome.
Literature
4.
17.
go back to reference Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020:e201834. https://doi.org/10.1001/jamacardio.2020.1834. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020:e201834. https://​doi.​org/​10.​1001/​jamacardio.​2020.​1834.
Metadata
Title
Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand’s university-based referral hospital
Authors
Rujipas Sirijatuphat
Yupin Suputtamongkol
Nasikarn Angkasekwinai
Navin Horthongkham
Methee Chayakulkeeree
Pinyo Rattanaumpawan
Pornpan Koomanachai
Susan Assanasen
Yong Rongrungruang
Nitipatana Chierakul
Ranistha Ratanarat
Anupop Jitmuang
Walaiporn Wangchinda
Wannee Kantakamalakul
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2021
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-021-06081-z

Other articles of this Issue 1/2021

BMC Infectious Diseases 1/2021 Go to the issue